Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462587 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II
A Phase 3 study of Leukocyte Adhesion Deficiency, sponsored by AUG Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05462587: Recruiting Phase 3 study of Leukocyte Adhesion Deficiency, sponsored by AUG Therapeutics.
NCT05462587 is a Phase 3 study of Leukocyte Adhesion Deficiency that is actively recruiting participants, run by AUG Therapeutics. The registered enrollment target is 4 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05462587, a Phase 3 study of Leukocyte Adhesion Deficiency, is actively recruiting participants, sponsored by AUG Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Primary Outcome
To assess the effect of AVTX-803 in subjects with leukocyte adhesion deficiency Type II (LAD II) by evaluating Sialyl-Lewis X on leukocytes as a percentage present at the end of each 8 week treatment period.
Conditions Studied
Interventions
- DRUG AVTX-803 (L-Fucose)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 3 |
What NCT05462587 shows while recruiting
NCT05462587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Leukocyte Adhesion Deficiency appearing as the primary indexed condition, and to 1 intervention - of which AVTX-803 (L-Fucose) is the first listed.
NCT05462587 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05462587 about?
NCT05462587 is a clinical study titled "A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II". The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
What is the current status of trial NCT05462587?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2022-07-28. Estimated completion is 2024-11-30.
What conditions does trial NCT05462587 study?
This clinical trial studies the following conditions: Leukocyte Adhesion Deficiency.
What interventions are being tested in trial NCT05462587?
The interventions under investigation include: AVTX-803 (L-Fucose) (DRUG).
Who is sponsoring clinical trial NCT05462587?
This trial is sponsored by AUG Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05462587 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukocyte Adhesion Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05462587's enrollment target sits among peer trials
4 1999th of 2000 higher than 2 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI